Next Article in Journal
Bactericidal Activity of Non-Cytotoxic Cationic Nanoparticles against Clinically and Environmentally Relevant Pseudomonas spp. Isolates
Previous Article in Journal
Formulation Development of Sublingual Cyclobenzaprine Tablets Empowered by Standardized and Physiologically Relevant Ex Vivo Permeation Studies

Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells

Department of Pharmacology, School of Dentistry, Kyungpook National University, Daegu 41940, Korea
Department of Biochemistry, Department of Convergence Medical Science, Institute of Health Sciences, College of Medicine, Gyeongsang National University, Jinju 52727, Korea
Division of Cosmetic Science and Technology, Daegu Haany University, Gyeongsan 38610, Korea
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Carlos Alonso-Moreno
Pharmaceutics 2021, 13(9), 1410;
Received: 30 June 2021 / Revised: 25 August 2021 / Accepted: 2 September 2021 / Published: 6 September 2021
Glioblastoma is an actively growing and aggressive brain tumor with a high propensity of recurrence. Although the surgical removal of tumor mass is the primary therapeutic option against glioblastoma, supportive pharmacotherapy is highly essential due to incredibly infiltrative characteristic of glioblastoma. Temozolomide, an FDA-approved alkylating agent, has been used as a first-line standard pharmacological approach, but several evident limitations were repeatedly reported. Despite additional therapeutic options suggested, there are no medications that successfully prevent a recurrence of glioblastoma and increase the five-year survival rate. In this study, we tested the possibility that finasteride has the potential to be developed as an anti-glioblastoma drug. Finasteride, an FDA-approved medication for the treatment of benign prostate hyperplasia and androgenic alopecia, is already known to pass through the blood–brain barrier and possess antiproliferative activity of prostate epithelial cells. We showed that finasteride inhibited the maintenance of glioma stem-like cells and repressed the proliferation of glioblastoma. Mechanistically, finasteride lowered intracellular ROS level by upregulating antioxidant genes, which contributed to inefficient β-catenin accumulation. Downregulated β-catenin resulted in the reduction in stemness and cell growth in glioblastoma. View Full-Text
Keywords: glioblastoma; finasteride; proliferation; β-catenin glioblastoma; finasteride; proliferation; β-catenin
Show Figures

Figure 1

MDPI and ACS Style

Kim, H.J.; Kim, T.-J.; Kim, Y.G.; Seong, C.; Cho, J.-H.; Kim, W.; Lee, K.-H.; Kim, D.-Y. Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells. Pharmaceutics 2021, 13, 1410.

AMA Style

Kim HJ, Kim T-J, Kim YG, Seong C, Cho J-H, Kim W, Lee K-H, Kim D-Y. Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells. Pharmaceutics. 2021; 13(9):1410.

Chicago/Turabian Style

Kim, Hyeon J., Tae-Jun Kim, Yu G. Kim, Chaeeun Seong, Jin-Hwa Cho, Wanil Kim, Kyung-Ha Lee, and Do-Yeon Kim. 2021. "Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells" Pharmaceutics 13, no. 9: 1410.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop